Creative Medical Technology (CELZ) Expected to Announce Quarterly Earnings on Friday

Creative Medical Technology (NASDAQ:CELZ) is anticipated to release its results before the market opens on Friday, March 13th. Analysts expect Creative Medical Technology to post earnings of ($0.37) per share for the quarter.

Creative Medical Technology Trading Down 0.5%

NASDAQ CELZ opened at $1.85 on Friday. The company has a market cap of $4.77 million, a P/E ratio of -0.64 and a beta of 2.09. The company has a fifty day simple moving average of $1.97 and a 200 day simple moving average of $2.72. Creative Medical Technology has a 12-month low of $1.50 and a 12-month high of $6.43.

Analysts Set New Price Targets

Several equities research analysts have recently commented on CELZ shares. Wall Street Zen downgraded shares of Creative Medical Technology from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Creative Medical Technology in a report on Monday, December 29th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce”.

Hedge Funds Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC purchased a new stake in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 1.17% of Creative Medical Technology as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 1.42% of the company’s stock.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.